Lv4
800 积分 2023-06-12 加入
The adenosine pathway in immuno-oncology
22天前
已完结
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy
29天前
已完结
Transarterial Chemoembolization and Immunotherapy: Another Good Marriage?
1个月前
已关闭
TIGIT’s immuno-oncology teachings
1个月前
已完结
OA08.01 BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007
2个月前
已关闭
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
2个月前
已完结
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3个月前
已完结
Significance and Utility of Immunohistochemical MTAP Expression to Predict CDKN2A Genomic Status in Diffuse Large B‐Cell Lymphoma
3个月前
已完结
皖公网安备34019202002308
